

Clinical trial information

Registration Item	Details of registration Item	Contents
Title of the study	Title of the study	A Phase III, Double-Blind, Non-inferiority Study of Favipiravir versus Oseltamivir Phosphate in Patients with Influenza Virus Infection
	Primary sponsor	Toyama Chemical Co., Ltd.
	Study Type	Interventional (drug)
	Summary	The primary objective of this study is to demonstrate non-inferiority of favipiravir against oseltamivir phosphate
Details of study	Interventional drug name	T-705a
	Target illness	Influenza infection
	Classification name (code) of the investigational drug	625 (anti-virus agents)
	Administration route	Oral administration
	Control drug name(code/td)	Oseltamivir Phosphate
	Classification name (code) of the investigational drug	625 (anti-virus agents)
	Administration route	Oral administration
	Objectives of the study	Medical treatment
	Study phase	Phase 3
	Study design	Double blind test
	Inclusion Criteria	<ul style="list-style-type: none"> • Patients aged between 20 and 74 • Patients who show a positive reaction to influenza virus antigen using a test kit from nasal or pharyngeal swabs; • Patients with 2 or more of the following symptoms(moderate to severe in severity)
	Outcome	Efficacy and safety
	Study status	Ongoing
	Duration of the study	2009-10~2010-6
Region	Japan,Korea,Taiwan	
Contact information	Organization	Toyama Chemical Co., Ltd.
	Division	Clinical Planning Department
	Fax and URL	FAX : 03-3342-5145 https://www.toyama-chemical.co.jp/en/contact/form/clinical/index.cgi